Rick Bienkowski
Stock Analyst at Leerink Partners
(0.49)
# 1,619
Out of 4,654 analysts
33
Total ratings
18.52%
Success rate
-26.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Upgrades: Outperform | $27 → $39 | $26.31 | +48.23% | 10 | Nov 6, 2024 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $95.08 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $15.12 | +329.89% | 7 | Jun 24, 2024 | |
| LEGN Legend Biotech | Initiates: Overweight | $82 | $39.89 | +105.57% | 1 | Apr 3, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $2.09 | - | 1 | Nov 8, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $22 | $5.38 | +308.92% | 3 | Sep 13, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $2.77 | +405.42% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $46.85 | +128.39% | 4 | Aug 8, 2022 |
Beam Therapeutics
Nov 6, 2024
Upgrades: Outperform
Price Target: $27 → $39
Current: $26.31
Upside: +48.23%
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $95.08
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $15.12
Upside: +329.89%
Legend Biotech
Apr 3, 2024
Initiates: Overweight
Price Target: $82
Current: $39.89
Upside: +105.57%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $2.09
Upside: -
Verve Therapeutics
Sep 13, 2023
Reiterates: Neutral
Price Target: $22
Current: $5.38
Upside: +308.92%
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $2.77
Upside: +405.42%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $46.85
Upside: +128.39%